Published on Thursday, 15 November 2012 00:00 | Written by Liz Highleyman
A 12-week once-daily regimen of 2 direct-acting hepatitis C drugs — sofosbuvir (formerly GS-7977) and daclatasvir (formerly BMS-790052) — produced sustained virological response rates for treatment-naive patients in the 90% to 100% range, and appeared effective regardless of HCV subtype, IL28B pattern, or use of ribavirin, according to a late-breaker presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston. The developers are not planning further studies of this combination, however, leaving its fate uncertain.
Last year’s approval of the first direct-acting hepatitis C drugs ushered in a new era of treatment, but many patients and providers are holding out for all-oral therapy without pegylated interferon and its difficult side effects — and if possible without ribavirin, which causes anemia.
It has become difficult to keep track of the numerous investigational anti-HCV drugs in the pipeline and the many different combination regimens at various stages of the development process.
But one combination that stands out on the basis of early studies is Gilead Sciences’ once-daily nucleotide analog polymerase inhibitor sofosbuvir plus Bristol-Myers Squibb’s HCV NS5A replication complex inhibitor daclatasvir.